Skip to main content

Feasibility Study for the introduction into pre-clinical study domain of the first-of-a-kind Multi Organ On Device (MOOD) technology

Objective

Advances in molecular biology have significantly increased the understanding of the biology of different diseases. Nevertheless, these advances are not fully translated yet into improved treatments for patients, specifically for what pertains to the oncological disorders. One of main reasons for this shortcoming is the lack of reliable in vivo models that accurately predict drug efficacy and toxicity, so to translate these results from preclinical studies to the clinic. In present project we address the major challenge of the preclinical stage in drug development, by offering a proprietary Multi-Organ-On-Device (MOOD), being an advanced fluidic multi-chamber bioreactor, a 3D model of breast cancer tissue cultured onto a membrane mimicking the blood vessel barrier, which jointly reproduce the physio mimetic environment of the cancer disease. In this way, MOOD technology enables the execution of standard pre-clinical assays, such as tumor cell migration and intravasation, drug efficacy and toxicity assays, thus bypassing unreliable, costly and ethically relevant mice studies. The validation of the MOOD device paves the way for the replacement, reduction and refinement (3Rs) of animal studies on global scale, allowing for dramatic cost reduction in the pre-clinical stage and for accelerated time to market for pharmaceutical companies and CROs. The objectives of this feasibility study will be the deep understanding of the market and its technological and economic requirements, so to properly stream line the industrialization of MOOD platform. We expect our MOOD technology to exert a disruptively beneficial impact on drug development process and thus, human health and national economies.

Field of science

  • /social sciences/economics and business/business and management/commerce
  • /social sciences/sociology/social problems/migration
  • /natural sciences/biological sciences/molecular biology
  • /engineering and technology/environmental biotechnology/bioremediation/bioreactor
  • /medical and health sciences/clinical medicine/oncology/cancer
  • /medical and health sciences/clinical medicine/oncology/cancer/breast cancer

Call for proposal

H2020-SMEInst-2018-2020-1
See other projects for this call

Funding Scheme

SME-1 - SME instrument phase 1

Coordinator

REACT4LIFE SRL
Address
Via Domenico Fiasella 1
16121 Genova
Italy
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 50 000